The aspirin cardiovascular/gastrointestinal risk calculator - A tool to aid clinicians in practice

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 7, 2013, Pages 738-748

  Lanas, A ^a   Polo Tomas M ^a   Casado Arroyo, R ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL RISK; HELICOBACTER INFECTION; HUMAN; INFECTION CONTROL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ASPIRIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84874650996     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12240     Document Type: Article

References (38)

1. Available at: http://www.who.int/en/
2. Lanas A,. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011; 10: 45-54.
3. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.
4. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 89-95.
5. Hansson L, Zanchetti A, Carruthers SG, et al,. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62. (Pubitemid 28269185)
6. Patrono C, Baigent C, Hirsh J, Roth G,. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines. Chest 2008; 133 (Suppl.): 199S-233S. (Pubitemid 351894914)
7. Antithrombotic Trialists' (ATT) Collaboration;, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A,. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-Analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
8. Ridker P, Cook NR, Lee IM, et al,. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
9. García Rodríguez LA, Hernández-Díaz S, De Abajo FJ,. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52: 563-71.
10. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S,. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123: 1108-15.
11. CAPRIE Steering Committee,. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
12. Bhatt DL, Fox KA, Hacke W, et al,. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706-17.
13. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
14. Anand S, Yusuf S,. Oral anticoagulant therapy in patients with coronary artery disease: a meta-Analysis. JAMA 1999; 282: 2058-67.
15. Sung JJ, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW,. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010; 105: 84-9.
16. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al,. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 1633-41.
17. Bhatt DL, Scheiman J, Abraham NS, et al,. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
18. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB,. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47. (Pubitemid 28213628)
19. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
20. Peto R, Gray R, Collins R, et al,. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-6. (Pubitemid 18042841)
21. CURE Study Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
22. Chen ZM, Jiang LX, Chen YP, et al,.; COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
23. Pignone M, Alberts MJ, Colwell JA, et al,. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694-701.
24. Hernandez-Diaz S, Garcia Rodriguez LA,. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006; 4: 22.
25. Abraham NS, Hlatky MA, Antman EM, et al,. 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA. 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 56: 2051-66.
26. Lanas A, Wu P, Mills EJ,. Low dose aspirin and bleeding-related adverse events: a meta-Analysis. Clin Gastroenterol Hepatol 2011; 9: 762-8.
27. Gisbert JP, Calvet X, Cosme A, et al,. Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol 2012; 107: 1197-204.
28. Chan FK, Chung SC, Suen BY, et al,. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73. (Pubitemid 32240315)
29. Lai KC, Lam SK, Chu KM, et al,. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8. (Pubitemid 34680594)
30. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al,.; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
31. Douglas IJ, Evans SJ, Hingorani AD, et al,. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 2012; 10: e4388.
32. Rostom A, Dube C, Wells GA, et al,. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
33. Ng FH, Wong SY, Lam KF, et al,. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138: 82-8.
34. The Society for Cardiac Angiography and Interventions. Available at: http://www.scai.org.
35. Iijima K, Ara N, Abe Y, et al,. Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level. J Gastroenterol 2012; 47: 1290-7.
36. Delaney JA, Opatrny LA, Brophy JM, Suissa S,. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-51. (Pubitemid 47339530)
37. Hernández-Díaz S, Rodríguez LA,. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9. (Pubitemid 30482713)
38. Lanas A, Bajador E, Serrano P, et al,. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-9.